Navigation Links
Selexis Announces Expansion of R&D License Agreement with Amgen
Date:2/20/2013

GENEVA, Feb. 20, 2013 /PRNewswire/ -- Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line™ for research and development.  Under the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line™ in conjunction with the Selexis SUREtech Vectors™ for improved R&D. 

(Logo: http://photos.prnewswire.com/prnh/20120627/LA31604LOGO)

"Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable," said Igor Fisch , Ph.D., President and CEO of Selexis. "Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently.  This current agreement is built on the long-standing relationship between our two companies since 2004." 

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information, visit http://www.selexis.com

Media Inquires
Robert Meister
Selexis SA
Tel: +1 (602) 953-1716
Email: robert.meister@selexis.com

 


'/>"/>
SOURCE Selexis SA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
2. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
3. Incisive Surgical Announces Sale Of One-Millionth INSORB Stapler
4. BioMed Realty Trust Announces Exercise Of Option To Purchase Additional Shares Of Common Stock
5. UBM Canon, the Global Authority on the MedTech Industry, Announces Senior Editor for MD+DI (Medical Device & Diagnostic Industry)
6. Silver Lining Textiles, Manufacturers of Anti-microbial Under Scrub Garments for the Healthcare Industry, Announces Their Availability Through Amazon.com
7. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
8. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
9. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
10. Vomaris Announces initiation of study with Walter Reed National Military Medical Centers Combat Wound Initiative
11. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2019)... CHICAGO (PRWEB) , ... July 19, 2019 , ... ... Meeting, September 11-13, in Phoenix, will provide strategies to keep pathologists, laboratory professionals ... stewardship techniques to improve outcomes and enhance patient care. , Renowned Speakers ...
(Date:7/19/2019)... , ... July 19, 2019 , ... Robinson Pharma, Inc., ... means that the facilities was audited by the Safe Quality Food (SQF) Institute using ... the SQF Food Safety Code for Manufacturing, Edition 8. , The SQF Certification program ...
(Date:7/18/2019)... ... July 18, 2019 , ... ... needs in the field of urology, today announced that Timothy Lesser, MD, Skyline ... The designation recognizes that Dr. Lesser has achieved a high level of training ...
Breaking Medicine Technology:
(Date:7/17/2019)... ... July 17, 2019 , ... ... plans participating in Medicare Advantage, Medicaid, and Marketplace programs is pleased to announce ... Electronic Health Records (EHR) integration at the point of care to ...
(Date:7/17/2019)... ... July 17, 2019 , ... ... client engagement options for human services providers worldwide, has been awarded a California ... program streamlines the procurement process for state and local government agencies in California ...
(Date:7/17/2019)... ... July 17, 2019 , ... The Coalition of Medication-Assisted Treatment ... seven of its member Opioid Treatment Programs (OTPs) at 12 locations are participating ... virus (HCV) with the goal of achieving better outcomes through telemedicine. The study, ...
(Date:7/13/2019)... ... ... Dr. Rupa Jolly, dentist and wife of Dr. Tarun Jolly of Tarun ... New Orleanians in 2019. She joins more than 20 other locals on the list, ... on the New Orleans community. , Combining their backgrounds in science and medicine, Dr. ...
(Date:7/13/2019)... CHARLOTTE, N.C. (PRWEB) , ... July 12, 2019 ... ... brand (NYSE American: YCBD), has been named a “Brand to Watch” by Brightfield ... Brightfield Group ranked cbdMD in the top 10 of domestic CBD companies in ...
Breaking Medicine News(10 mins):